The TGA has strengthened its warning on the use of febuxostat (Adenuric) to include all gout patients with pre-existing major cardiovascular disease. The PI for the gout drug had previously included a warning that it was not recommended for patients with ischaemic heart disease or congestive heart failure. However, the TGA says its position has ...
TGA strengthens febuxostat heart warning
8 Oct 2019